Technology evaluation: tgDCC-E1A, targeted genetics/MD Anderson

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 2, 1999, Pages 266-270

  Wagner, John A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMID DNA;

ARTICLE; BREAST TUMOR; CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENE EXPRESSION; GENE INACTIVATION; GENE TARGETING; GENE THERAPY; HUMAN; ONCOGENE; OVARY TUMOR; PHASE 2 CLINICAL TRIAL; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ADENOVIRUS E1A PROTEINS; ANIMALS; CLINICAL TRIALS; GENE THERAPY; GENES, DCC; GENETIC VECTORS; HUMANS; NEOPLASMS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

ANIMALIA;

EID: 0033004849     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Targeted Genetics Corp: Targeted Genetics receives SBIR grants to scale-up manufacturing of AAV-CFTR product for cystic fibrosis, and to support human trials of HER-2/neu inhibitor product for breast and ovarian cancer. Press Release October 10 (1996).
2. Clinical trials update. Scrip (1996) 21(75):19.
3. Targeted Genetics 70-day success in CF trial. Scrip (1996) 21(78):23.
4. Xie Y, Hung MC: p66(Shc) isoform down-regulated and not required for HER-2/neu signaling pathway in human breast cancer cell lines with HER-2/neu overexpression. Biochem Biophys Res Commun (1996) 221(1):140-145.
5. Yu D, Matin A, Xia W, Sorgi F, Huang L, Hung MC: Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogens (1995) 11(7):1383-1388.
6. Fisk B, Chesak B, Pollack MS, Wharton JT, Ioannides CG: Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/Neu proto-oncogene in vitro. Cell Immunol (1994) 157(2):415-427
7. Targeted Genetics Corp: Targeted Genetics begins second phase I clinical trial of E1A tumor suppressor gene product; multicenter trial tests tgDCC-E1A as potential treatment for cancer patients. Press Release April 29 (1997).
8. Targeted Genetics Corp: Targeted Genetics reports first quarter financial results. Press Release May 1 (1997).
9. Targeted Genetics Corp: Targeted genetics receives $1 million milestone payment from Fournier for enrollment of patients in trial of HER-2/neu inhibitor. Press Release October 1 (1996).
10. Targeted Genetics Corp: Annual Report December (1996).
11. Targeted Genetics Corp: Targeted Genetics receives $1 million milestone payment; regulatory approval received to start European clinical trials. Press Release July 24 (1997).
12. Targeted Genetics Corp: Gene therapy technology overview. Company Brochure March (1997).
13. Targeted Genetics Corp: Delivering innovation in gene therapy; Targeted Genetics Corp. Company Brochure March (1997).
14. Targeted Genetics Corp: Targeted Genetics reports second quarter 1997 financlals. Press Release July 31 (1997).
15. Targeted Genetics Corp: Targeted Genetics receives three patents on tumor suppressor genes for broad use in gene therapy products for cancer. Press Release August 18 (1997).
16. Targeted Genetics Corp: Targeted Genetics reports third quarter 1997 financial results. Press Release October 30 (1997).
17. Molecular Determinants of Cancer Metastasis 50th Annual Symposium Fundamental Cancer Research, Houston, TX, USA. Iddb Meeting Report October 28-31 (1997).
18. Targeted Genetics Corp: Gene therapy technology overview. Company Brochure March (1997).
19. Targeted Genetics Corp: Targeted Genetics announces presentation of phase I clinical data of tgDCC-E1A for cancer at upcoming medical meeting/tgDCC-E1A shown safe; product development moves forward. Press Release February 10 (1998).
20. Targeted Genetics Corp: Targeted Genetics announces restructuring. Press Release February 13 (1998).
21. Targeted Genetics Corp: Targeted Genetics Reports Fourth Quarter and Year-End 1997 Financial Results. Press Release March 27 (1998).
22. Ueno NT, Hung MC, Zhang S, Xia W, Willey JS, Warner DL, Payne JY, Nandagiri R, Aldridge R, De Jager RL, Tucker S, et al: Phase 1 E1A gene therapy in patients with advanced breast and ovarian cancers. Proc Am Assoc Cancer Res (1998) 39:Abs2458.
23. American Association For Cancer Research 89th Annual Meeting (Part III): Cell-based gene therapy and late-breaking news, New Orleans, LA, USA. Iddb Meeting Report March 28-April 1 (1998).
24. Ueno NT, Yu D, Hung MC: Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene (1997) 15(8):953-960.
25. Ueno NT, Yu D, Hung MC: Chemosensitization of HER-2-neu-overexpressed breast cancer cells to paclitaxel by adenovirus 5 E1A. Proc Am Assoc Cancer Res (1996) 37: 340
26. Targeted Genetics collaborators report additional phase I E1A gene therapy data at American Society of Clinical Oncology meeting. Targeted Genetics Corp. Press Release. May 18 (1998).
27. Hutchinson E: American Society of Gene Therapy First Annual Meeting (Part I) Education Session: The ABCs of Non-Viral Vectors for Gene Therapy, Seattle, WA, USA. Iddb Meeting Report May 28-31 (1998).
28. Ueno NT, Hung MC, Weiden P, Wolf JK, Xia W, Zhang S, Daifuku R, Kilbourn RG, Willey JS, Warner DL, Payne JY: Phase I trial of E1A gene therapy in patients with advanced breast and ovarian cancers. Am Soc Gene Therapy (1998):96-383.
29. http://www.targen.com. Company Worldwide Website (1998).
30. Targeted Genetics Corp: Targeted Genetics announces issuance of broad patent for lipid-based gene delivery systems for use in gene therapy. Press Release August 18 (1998).
31. Targeted Genetics Corp: Targeted Genetics announces initiation of phase II trials for E1A tumor inhibitor gene therapy. Press Release October 5 (1998).
32. Chang JY, Xia W, Shao R, Sorgi F, Hortobagyi GN, Huang L, Hung M-C: The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogens (1997) 14:651-568.
33. Yu D, Wolf JK, Scanlon M, Price JE, Hung M-C: Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe maligancy that can be suppressed by E1A. Cancer (1993) 53:891-898.